The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients

Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses

(2019) Karim Vermaelen   Frontiers in Immunology

Turning the corner on therapeutic cancer vaccines

(2019) Robert E. Hollingsworth et al.   npj Vaccines

Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors

(2019) Patrick A. Ott et al.   Cancer Discovery

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

(2018) Brigitte Dreno et al.   LANCET ONCOLOGY

The complement system in cancer: Ambivalence between tumour destruction and promotion

(2017) Srinivas Mamidi et al.   IMMUNOBIOLOGY

The role of the complement system in cancer

(2017) Vahid Afshar-Kharghan   JOURNAL OF CLINICAL INVESTIGATION

Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate

(2017) Christelle Ganneau et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape

(2017) Abhishek D. Garg et al.   TRENDS IN IMMUNOLOGY

The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity

(2016) Daphné Laubreton et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

(2016) Avery D. Posey et al.   IMMUNITY

Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma

(2016) Sofie Wilgenhof et al.   JOURNAL OF CLINICAL ONCOLOGY

Peptide-based synthetic vaccines

(2016) Mariusz Skwarczynski et al.   Chemical Science

Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?

(2016) Robert O. Dillman   Human Vaccines & Immunotherapeutics

Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer

(2016) E. Scheid et al.   Cancer Immunology Research

Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen

(2016) C. Fu et al.   HLA

The Quest for Anticancer Vaccines: Deciphering the Fine-Epitope Specificity of Cancer-Related Monoclonal Antibodies by Combining Microarray Screening and Saturation Transfer Difference NMR

(2015) Helena Coelho et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases

(2015) Vashti Irani et al.   MOLECULAR IMMUNOLOGY

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody

(2014) L. Karyampudi et al.   CANCER RESEARCH

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

(2014) G. T. Gibney et al.   CLINICAL CANCER RESEARCH

Cytokine Diversity in the Th1-Dominated Human Anti-Influenza Response Caused by Variable Cytokine Expression by Th1 Cells, and a Minor Population of Uncommitted IL-2+IFNγ- Thpp Cells

(2014) Nan Deng et al.   PLoS One

Immature truncated O-glycophenotype of cancer directly induces oncogenic features

(2014) Prakash Radhakrishnan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Monoclonal antibodies toward different Tn-amino acid backbones display distinct recognition patterns on human cancer cells. Implications for effective immuno-targeting of cancer

(2013) Daniel Mazal et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

(2013) Wim H.J. Kruit et al.   JOURNAL OF CLINICAL ONCOLOGY

Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy

(2012) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant

(2010) T. Freire et al.   BLOOD

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model

(2009) S.-Y. Wang et al.   BLOOD

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

Mucin-type O-glycosylation and its potential use in drug and vaccine development

(2007) Mads Agervig Tarp et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS